Every player in a drug class on one page: who leads on Medicare spending, who owns each brand and when its protection ends, which molecules are still in trials, and who is running them.
Molecules with the same mechanism that are not yet approved in the US (ChEMBL), with their open trials. Programmes with no open trial come last: they may be paused or dropped.
Lead sponsors of open trials of any class member or entrant, by phase. Hover a bar for counts.
How to read this. Members are the approved drugs that share a mechanism (ChEMBL) or an FDA pharmacologic class. Share is each drug's part of the class's Medicare spending (Part D + Part B) in the latest full year with data for the whole class. Owners are the application holders in the Orange Book or Purple Book; "protection until" is the latest listed patent or exclusivity, and "copies on market" means a generic, biosimilar or interchangeable is approved and marketed. Open trials count recruiting or active ClinicalTrials.gov studies that name the drug.
What it is not. Spending is gross, before rebates, and covers public programs only, so shares are not US market shares. Listed protection is not a forecast of generic entry: litigation, settlements and unlisted patents change real dates. Pipeline molecules come from ChEMBL, which can lag company announcements. Not investment, legal or medical advice.